Bone disease and skeletal complications in patients with β thalassemia major

R Haidar, KM Musallam, AT Taher - Bone, 2011 - Elsevier
Increased survival in patients with β thalassemia major (TM) allowed for several
complications of the disease and its treatment to manifest, one of which is bone disease …

Bone disease in β thalassemia patients: past, present and future perspectives

V De Sanctis, AT Soliman, H Elsefdy, N Soliman… - Metabolism, 2018 - Elsevier
Bone disorders in patients with thalassemia major (TM) and intermedia (TI) constitute
complex conditions that result from various factors affecting the growing skeleton. Although …

[PDF][PDF] Bone disease in thalassemia: a frequent and still unresolved problem

MG Vogiatzi, EA Macklin, EB Fung… - Journal of Bone and …, 2009 - Wiley Online Library
Adults with β thalassemia major frequently have low BMD, fractures, and bone pain. The
purpose of this study was to determine the prevalence of low BMD, fractures, and bone pain …

CGRP may regulate bone metabolism through stimulating osteoblast differentiation and inhibiting osteoclast formation

H He, J Chai, S Zhang, L Ding… - Molecular …, 2016 - spandidos-publications.com
Calcitonin-gene-related peptide (CGRP) is a neuropeptide, which is widely distributed
throughout the central and peripheral nervous systems. Numerous mechanisms underlying …

Decreased bone formation explains osteoporosis in a genetic mouse model of hemochromatosiss

M Doyard, D Chappard, P Leroyer, MP Roth, O Loréal… - PloS one, 2016 - journals.plos.org
Osteoporosis may complicate iron overload diseases such as genetic hemochromatosis.
However, molecular mechanisms involved in the iron-related osteoporosis remains poorly …

Osteoprotegerin (OPG) und Receptor Activator for Nuclear Factor kappaB Ligand (RANKL) Bestimmung im Serum: Sinn oder Unsinn?

D Wagner, A Fahrleitner-Pammer - Wiener Medizinische Wochenschrift, 2010 - Springer
The coupling of bone formation and resorption is mediated through the OPG/RANK/RANKL
system. OPG and RANKL are mainly produced by osteoblasts but also a variety of other …

Free soluble receptor activator of nuclear factor‐κb ligand in gingival crevicular fluid correlates with distinct pathogens in periodontitis patients

D Sakellari, S Menti… - Journal of Clinical …, 2008 - Wiley Online Library
Aim: The aim of the experiment was to investigate the levels of free soluble receptor activator
of nuclear factor‐κb ligand (sRANKL) in periodontal health and disease and their …

The spine in β-thalassemia syndromes

R Haidar, H Mhaidli, KM Musallam, AT Taher - Spine, 2012 - journals.lww.com
Study Design. Literature review. Objective. To present a comprehensive overview of spinal
involvement in patients with β-thalassemia, aiming to orient the spinal surgeon to these …

RANKL inhibition for the management of patients with benign metabolic bone disorders

AD Anastasilakis, KA Toulis, SA Polyzos… - Expert opinion on …, 2009 - Taylor & Francis
The receptor activator of NF-κB ligand (RANKL) is a member of the TNF receptor
superfamily, essential for osteoclastogenesis. It binds to its receptor activator of NF-κB on the …

Active hematopoiesis triggers exosomal release of PRDX2 that promotes osteoclast formation

G Sadvakassova, K Tiedemann, KJD Steer… - Physiological …, 2021 - Wiley Online Library
Hematopoietic disorders, particularly hemolytic anemias, commonly lead to bone loss. We
have previously reported that actively proliferating cancer cells stimulate osteoclastogenesis …